AAPL 250.9362 1.1636% MSFT 439.85 0.5624% NVDA 132.26 2.5987% GOOGL 190.36 1.0403% GOOG 191.585 0.7547% AMZN 224.7026 1.8967% META 605.1 1.3245% AVGO 221.57 -0.9167% TSLA 434.8 -1.211% TSM 195.3 -0.133% LLY 758.87 -0.7637% V 315.9 1.9756% JPM 234.325 1.7168% UNH 493.79 -1.1867% NVO 103.7 -2.1329% WMT 93.89 0.3634% LVMUY 130.52 0.7721% XOM 105.67 -0.7048% LVMHF 649.5 0.6649% MA 526.755 1.3068%

Invitae Corp

Healthcare US NVTA

0.019USD
-0.0105(35.59%)

Last update at 2024-02-14T21:03:00Z

Day Range

0.020.02
LowHigh

52 Week Range

0.362.94
LowHigh

Fundamentals

  • Previous Close 0.03
  • Market Cap206.48M
  • Volume22459258
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-353.93699M
  • Revenue TTM481.58M
  • Revenue Per Share TTM1.86
  • Gross Profit TTM 99.05M
  • Diluted EPS TTM-5.36

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -3151.19700M -415.86300M -714.27000M -260.41500M -132.15500M
Minority interest - - - - -
Net income -3106.29300M -379.00600M -608.87000M -241.96500M -129.35500M
Selling general administrative 192.31M 248.07M 324.57M 79.07M 52.23M
Selling and marketing expenses 218.88M 225.91M 168.32M 122.24M 74.43M
Gross profit 99.05M 111.78M 81.32M 98.72M 67.59M
Reconciled depreciation 142.07M 80.47M 39.05M 16.21M 13.54M
Ebit -714.23600M -778.28700M -652.17200M -244.11200M -125.12500M
Ebitda -564.11100M -672.13700M -645.45400M -231.79700M -111.58500M
Depreciation and amortization 150.12M 106.15M 6.72M 12.31M 13.54M
Non operating income net other - 25.68M -32.33200M -3.89100M -2.56800M
Operating income -714.23600M -778.28700M -652.17200M -244.11200M -122.55700M
Other operating expenses 1230.54M 1238.74M 931.77M 460.94M 270.26M
Interest expense 56.75M 49.90M 29.77M 12.41M 7.03M
Tax provision -44.90400M -36.85700M -105.40000M -18.45000M -2.80000M
Interest income - - - 12.41M 7.03M
Net interest income -56.74700M -49.90000M -29.76600M -12.41200M -7.03000M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -44.90400M -36.85700M -105.40000M -18.45000M -2.80000M
Total revenue 516.30M 460.45M 279.60M 216.82M 147.70M
Total operating expenses 813.28M 890.07M 733.50M 342.83M 190.15M
Cost of revenue 417.26M 348.67M 198.28M 118.10M 80.11M
Total other income expense net -2436.96100M 362.42M -62.09800M -16.30300M -2.56800M
Discontinued operations - - - - -
Net income from continuing ops -3106.29300M -379.00600M -602.17000M -241.96500M -129.35500M
Net income applicable to common shares -3106.29300M -379.00600M -602.17000M -241.96500M -129.35500M
Preferred stock and other adjustments - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Total assets 1954.12M 4919.57M 3423.78M 781.60M 282.96M
Intangible assets 1012.55M 1187.99M 981.85M 125.17M 30.47M
Earning assets - - - - -
Other current assets 19.50M 33.69M 20.20M 18.03M 13.26M
Total liab 1852.28M 1941.17M 1454.19M 401.96M 121.12M
Total stockholder equity 101.84M 2978.40M 1969.59M 379.64M 161.84M
Deferred long term liab - 51.70M 51.54M - -
Other current liab 69.57M 97.02M 79.68M 63.38M 25.80M
Common stock 0.03M 0.02M 0.02M 0.01000M 0.00800M
Capital stock 0.03M 0.02M 0.02M 0.01000M 0.00800M
Retained earnings -4829.14100M -1722.84800M -1367.54700M -758.67700M -516.71200M
Other liab 12.90M 89.49M 892.79M 8.00M 8.96M
Good will 0.00000M 2283.06M 1856.92M 126.78M 50.09M
Other assets -3.85800M 33.83M 19.87M 7.26M 9.07M
Cash 257.49M 923.25M 124.79M 151.39M 112.16M
Cash and equivalents - - - - -
Total current liabilities 108.09M 144.09M 121.75M 81.86M 36.31M
Current deferred revenue 4.81M 9.43M 6.38M 1.43M 0.76M
Net debt 1493.51M 800.85M 325.34M 167.44M -34.36900M
Short term debt 19.72M 16.52M 10.48M 6.72M 1.94M
Short long term debt - - - - -
Short long term debt total 1751.00M 1724.10M 450.14M 318.83M 77.79M
Other stockholder equity 4931.03M 4701.23M 3337.12M 1138.32M 678.55M
Property plant equipment 215.29M 235.88M 66.10M 37.75M 27.89M
Total current assets 693.13M 1178.81M 453.93M 442.40M 165.44M
Long term investments - - - - 0.00000M
Net tangible assets -947.72200M -492.65500M -869.17500M 127.69M 81.28M
Short term investments 289.61M 122.12M 229.19M 240.44M 13.73M
Net receivables 96.15M 66.23M 47.72M 32.54M 26.30M
Long term debt 1593.12M 1577.53M 388.17M 268.75M 74.48M
Inventory 30.39M 33.52M 32.03M 6.60M 8.30M
Accounts payable 13.98M 21.13M 25.20M 10.32M 7.81M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -0.08000M -0.00700M 0.00100M -0.00900M -0.00500M
Additional paid in capital - - - - -
Common stock total equity - 0.02M 0.02M 0.01000M 0.00800M
Preferred stock total equity - - - - -
Retained earnings total equity - -1722.84800M -1360.84700M -758.67700M -516.71200M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 33.15M 33.83M 19.87M 12.86M 9.07M
Deferred long term asset charges - - - - -
Non current assets total 1260.99M 3740.76M 2969.85M 339.20M 117.52M
Capital lease obligations 157.89M 146.57M 61.96M 50.07M 1.38M
Long term debt total - 1577.53M 388.17M 268.75M 75.85M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -174.80300M 99.34M 10.06M -226.41700M 42.74M
Change to liabilities -2.46500M -9.25800M 27.73M 17.86M 3.15M
Total cashflows from investing activities -174.80300M -204.08000M -400.58300M -280.31000M 35.77M
Net borrowings -5.41000M 1112.67M 129.21M 254.26M 27.20M
Total cash from financing activities 1.76M 1565.94M 673.84M 464.77M 157.15M
Change to operating activities 3.92M -0.17700M 16.43M 13.34M 1.96M
Net income -3106.29300M -379.00600M -608.87000M -241.96500M -129.35500M
Change in cash -666.00600M 802.04M -26.09200M 39.41M 100.70M
Begin period cash flow 933.52M 131.48M 157.57M 118.16M 17.46M
End period cash flow 267.52M 933.52M 131.48M 157.57M 118.16M
Total cash from operating activities -492.96100M -559.81500M -299.35400M -145.05300M -92.22000M
Issuance of capital stock 17.82M 458.03M 547.89M 213.49M 129.95M
Depreciation 142.07M 80.47M 39.05M 16.21M 13.54M
Other cashflows from investing activities - -1.30000M -387.77900M -33.84600M -1.00000M
Dividends paid - - - - -
Change to inventory 3.13M -1.48600M -7.83200M 11.32M 2.12M
Change to account receivables -29.92100M -16.69600M -2.81400M -6.13100M -5.29100M
Sale purchase of stock - 23.77M 284.20M 9.47M 17.51M
Other cashflows from financing activities -10.64700M 1111.67M 130.95M 328.35M 89.30M
Change to netincome 2487.11M -247.89000M 160.17M 48.98M 26.98M
Capital expenditures 53.31M 54.72M 22.86M 20.05M 5.97M
Change receivables - -16.69600M -2.81400M -6.13100M -5.29100M
Cash flows other operating - -457.00600M 70.15M -2.95300M -1.24600M
Exchange rate changes - - - - -
Cash and cash equivalents changes - 802.04M -26.09200M 39.41M 100.70M
Change in working capital -25.34100M -27.61700M 15.97M 8.77M -3.75200M
Stock based compensation 199.30M 180.07M 158.75M 75.95M 20.85M
Other non cash items 2342.20M -376.88200M 201.15M 14.44M 9.36M
Free cash flow -546.27000M -614.53500M -322.21900M -165.10000M -98.19000M

Peer Comparison

Sector: Healthcare Industry: Diagnostics & Research

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
NVTA
Invitae Corp
-0.0105 35.59% 0.02 - - 0.40 3.32 2.99 -1.1261
TMO
Thermo Fisher Scientific Inc
2.81 0.54% 518.99 34.71 23.87 4.62 4.43 5.29 20.89
DHR
Danaher Corporation
-0.38 0.17% 227.92 29.09 28.01 5.67 3.20 6.00 19.09
IDXX
IDEXX Laboratories Inc
-0.4 0.10% 410.36 49.99 45.66 11.29 27.85 11.46 34.46
IQV
IQVIA Holdings Inc
-0.225 0.12% 190.75 37.82 19.68 2.76 7.20 3.61 17.03

Reports Covered

Stock Research & News

Profile

Invitae Corporation, a medical genetics company, that provides genetic information to improve healthcare of people in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, precision oncology, women's health, rare diseases, and pharmacogenomics; digital health solutions; and health data services. It serves patients, healthcare providers, biopharma companies, and other partners. The company was formerly known as Locus Development, Inc. and changed its name to Invitae Corporation in 2012. Invitae Corporation was incorporated in 2010 and is headquartered in San Francisco, California.

Invitae Corp

1400 16th Street, San Francisco, CA, United States, 94103

Key Executives

Name Title Year Born
Mr. Kenneth D. Knight Pres, CEO & Director 1961
Ms. Yafei Wen Chief Financial Officer 1973
Mr. Thomas R. Brida Gen. Counsel, Chief Compliance Officer & Sec. 1971
Dr. Robert L. Nussbaum M.D. Chief Medical Officer 1950
Ms. Shelly D. Guyer Chief Sustainability Officer 1960
Mr. Robert F. Werner Chief Accounting Officer & Principal Accounting Officer 1973
Ms. Hoki Luk Head of Investor Relations and Capital Markets 1976
Mr. Lee Bendekgey J.D. Chief Policy Officer 1958
Glenn Medalle Head of Talent NA
Ms. Desarie French Chief Talent Officer NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.